Nature`s Sunshine Products Overview
Nature`s Sunshine Products (NATR) has a ROE of 10.69%, below the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow10.69%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for NATR is 10.69%. That is below the Healthcare sector average of 20.86%. Investors often review this figure alongside Nature`s Sunshine Products's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, NATR currently prints 10.69% for ROE, while the sector average sits near 20.86%. That is roughly 48.8% below the sector mean. Large gaps often invite a closer look at Nature`s Sunshine Products's growth, margins, and balance sheet.
Return on Equity shows how effectively Nature`s Sunshine Products converts resources into returns. At 10.69%, NATR may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NATR's ROE (10.69%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Nature`s Sunshine Products's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
